Additional Relevant Details Pluristem Therapeutics announced that they received FDA clearance to initiate Phase 1 clinical trials of their PLX-R18 therapy drugs.  The first trial is expected to begin in the 1H of 2016.  PLX-R18 cells are used to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT).  The Company also says that they intend to pursue early market access for PLX-R18 in the U.S.